Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Drugstore chain CVS disclosed Thursday that it will sell a rival, generic version of Mylan's EpiPen for about one-sixth of the price, according to CNN Money.
Here are seven articles published by Becker's Hospital Review in the past week that offer insight on controversy surrounding the drug industry, the benefits of a career in supply chain and more.
The time has come for drug companies to get serious about making a deal with the government over high drug prices, according to Jake Novak, a senior columnist for CNBC.
The Food and Drug Administration Wednesday issued a warning over the use of implantable infusion pumps in MRIs.
While the political views of Vermont Sen. Bernie Sanders (I) and President-elect Donald Trump fall on opposite sides of the spectrum, the two men found common ground on one topic: high drug costs.
Richard Gonzalez, the CEO of AbbVie, said the company will not raise drug prices past the single digits in 2017, reports Reuters.
The National Cancer Institute is creating an ambitious new program that will enable scientists to access new drugs and compounds faster for medical research, according to STAT.
The release of abuse-deterrent OxyContin directly coincides with the surging rates of heroin overdose deaths, according to a new working paper from researchers at the RAND Corp. and the Wharton School.
Beginning in February, New Brunswick, N.J.-based Johnson & Johnson will divulge price increases for its prescription drugs, reports The Washington Post.
Charlotte, N.C.-based SonaCare Medical earned clearance from the Food and Drug Administration for a new version of its Sonablate device.